Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18402760 | 1.00 | GAA (0.46) | GAAMAPTHTR2ARETHTR2C | |
| Hydrochloric Acid SCHEMBL27699649 | 0.98 | GAA (0.44) | GAAMAPTHTR2ARETHTR2C | |
| SCHEMBL7381467 | 0.85 | HTR2A (0.46) | GAAMAPTHTR2AHRH1AR | |
| SCHEMBL11426860 | 0.82 | GAA (0.47) | GAAMAPTARPNMTCREBBP | |
| SCHEMBL3972852 | 0.81 | MTNR1A (0.52) | GAAMAPTHTR2ARETHTR2C | |
| SCHEMBL8907137 | 0.80 | GAA (0.46) | GAAMAPTARPNMTCREBBP | |
| SCHEMBL2450511 | 0.80 | CREBBP (0.59) | GAAMAPTARPNMTCREBBP | |
| SCHEMBL22955423 | 0.80 | CREBBP (0.59) | GAAMAPTARPNMTCREBBP | |
| SCHEMBL1193549 | 0.80 | CREBBP (0.59) | GAAMAPTARPNMTCREBBP | |
| SCHEMBL550431 | 0.80 | CREBBP (0.59) | GAAMAPTARPNMTCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108822690-A | Keep the temperature corrosion-resistant coating container, container keeps the temperature corrosion-resistant coating process | 上海鸣昂机械科技有限公司 | 2018-11-16 | — | — | CN | claimed |
| CN-103467355-A | Preparation method of indapamide | DISHA PHARMACEUTICAL GROUP CO | 2013-12-25 | — | — | CN | claimed |
| CN-101029017-A | Production indapamide | HUAHAI PHARMACEUTICAL CO LTD Z (CN) | 2007-09-05 | — | — | CN | claimed |
| EP-0001546-A1 | 2-Guanidinomethyl-indolines, method for their preparation and their pharmaceutical use | Merck Patent GmbH (DE) | 1979-05-02 | — | — | EP | claimed |
| US-20170340749-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| EP-1867654-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | NAGOYA IND SCIENCE RES INST (JP) | 2014-06-11 | — | — | EP | disclosed |
| CN-103467355-A | Preparation method of indapamide | DISHA PHARMACEUTICAL GROUP CO | 2013-12-25 | — | — | CN | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| CN-101215256-B | 2-methylamino(4,7-dihydroindole) compound, synthetic method and use thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2011-12-07 | — | — | CN | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
| CN-101029017-A | Production indapamide | HUAHAI PHARMACEUTICAL CO LTD Z (CN) | 2007-09-05 | — | — | CN | disclosed |
| US-5616586-A | Tricyclic quinoxalinediones | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0642508-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993008188-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-04-29 | — | — | WO | disclosed |
| US-4260628-A | 2-Guanidinomethyl-indolines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-04-07 | — | — | US | disclosed |
| EP-0001546-A1 | 2-Guanidinomethyl-indolines, method for their preparation and their pharmaceutical use | Merck Patent GmbH (DE) | 1979-05-02 | — | — | EP | disclosed |
| EP-0001546-A1 | 2-Guanidinomethyl-indolines, method for their preparation and their pharmaceutical use | Merck Patent GmbH (DE) | 1979-05-02 | — | — | EP | disclosed |
| US-3980797-A | Hexahydro-diazepino-indole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340749-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | GAA 2047/4885MAPT 4072/4885HTR2A 1035/4885 |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | GAA 503/4885MAPT 2486/4885HTR2A 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.